Pharma’s rough patch deepens as fines, clinical failures and market fallout put safety, efficacy and investor confidence under pressure.
India’s biopharma sector is gaining regulatory strength as Biopharma SHAKTI and IPC’s quality push support biologics and biosimilars growth.
USFDA inspections across three Indian-linked pharma facilities reveal varied compliance outcomes, from minimal observations to Form 483 and VAI classification.
MSD has inaugurated a technology centre in Hyderabad, strengthening its global technology network and supporting Human Health through digital and enterprise capabilities.
India’s race to eliminate cervical cancer gains momentum as HPV vaccination crosses 80 lakh doses, strengthening the country’s prevention efforts.
Alembic’s Vadodara facility completes a major compliance turnaround, moving from a warning letter to a zero-observation USFDA inspection.
Glenmark's RYALTRIS brings dual-action therapy to Brazil, expanding treatment options for patients with moderate to severe allergic rhinitis symptoms.
Trial results today are reshaping pharma fortunes, with clinical successes boosting confidence while failures trigger sharp market reactions.
Natco Pharma plans a ?1,300 crore rights issue as it builds funding capacity for M&A. The move adds to its QIP plan and ?3,500 crore cash reserves for strategic acquisitions.
China’s Wegovy approval for MASH strengthens Novo Nordisk’s global position, extending the GLP-1 drug’s reach from weight management into liver disease.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")